The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is characterized by an enlarged prostate, lower urinary tract symptoms (LUTS), and a decreased urinary flow rate. Common in older men, BPH is a progressive disease that can eventually lead to complications including acute urinary retention (AUR) and the need for BP...
Saved in:
| Main Authors: | Eric H. Kim, John A. Brockman, Gerald L. Andriole |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-01-01
|
| Series: | Asian Journal of Urology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214388217300929 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Possibilities of Therapeutic and Prophylactic Tactics in Management of Benign Prostatic Hyperplasia in Tuberculosis Patients
by: Z. R. Rashidov, et al.
Published: (2021-08-01) -
Assessment of novel biomarkers of renal dysfunction associated with lower urinary tract symptoms in men with benign prostatic hyperplasia
by: V. Yu. Startsev, et al.
Published: (2024-11-01) -
Prostatic Artery Embolization for Benign Prostatic Hyperplasia—A Primer for Interventional Radiologists
by: Tiago Bilhim, et al.
Published: (2021-07-01) -
Testosterone and 5 Alpha Reductase Inhibitor (5ARI) in Benign Prostatic Hyperplasia (BPH): A historical perspective
by: Ananias C. Diokno, et al.
Published: (2024-12-01) -
Silodosin — a safer alpha-blocker targeting benign prostatic hyperplasia
by: Karen Koch
Published: (2015-09-01)